EdRip and Forbion lead funding for Allecra Therapeutics

Forbion and EdRip were also joined by EMBL Ventures in the round. Allecra will use the funding to support early clinical development of two new antibiotic treatments designed to combat multi drug-resistant gram-negative bacteria.

Allecra was the first investment of EdRip's new life sciences fund Biodiscovery 4, which was announced in July 2012. The business was set up as a strategic partnership between the company's founders, including CEO Nicholas Benedict, in conjunction with Orchid Chemicals & Pharmaceuticals Ltd (India) and the two lead investors EdRip and Forbion.

Company
Set up in 2013, Allecra is situated in the European BioValley Life Sciences cluster, located in the Upper Rhine Valley, encompassing north-west Switzerland, south-eastern Germany and the Alsace Region of France. The biotech business focuses on the development of novel treatments to combat multi-drug-resistant bacterial infections with the mission to contribute towards the global effort to combat antibiotic resistance.

People
Olivier Litzka is partner at EdRip and board director at Allecra, while Holger Reithinger is board member of Allecra and partner at Forbion. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Switzerland
• France
• Germany
• Rothschild